Sagimet Biosciences Announces Publication of Results from
- Treatment with denifanstat achieved statistically significant and clinically meaningful improvements in disease activity, MASH resolution and fibrosis -- Results ...
Read more- Treatment with denifanstat achieved statistically significant and clinically meaningful improvements in disease activity, MASH resolution and fibrosis -- Results ...
Read moreSAN MATEO, Calif., Oct. 01, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Sagimet, Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel ...
Read moreSAN MATEO, Calif., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (“Sagimet”) (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing ...
Read moreCombination treatment of a FASN inhibitor with semaglutide, a GLP-1 receptor agonist, improved several biomarkers associated with NASH in a ...
Read more© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.
© 2015 - 2024 LifeCare News - LIFE CARE IS REGISTERED MAGAZINE IN RNI, NO.GUJGUJ/2015/71283 - Lifecarenews.in.